Drug intelligence / Profile preview

adenovirus type 4 and type 7 vaccine, live, oral

Development stage: Approved
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Vaccines & Immunotherapeutics
Administration: Oral

Overview

**Adenovirus Type 4 and Type 7 Vaccine, Live, Oral** is a live, bivalent oral vaccine developed under the code **DR-5001** to prevent febrile acute respiratory disease caused by human adenovirus types 4 and 7 in military populations. A complete dose consists of two enteric-coated tablets, one containing live adenovirus type 4 and one containing live adenovirus type 7. The product induces active type-specific immune responses and is FDA-approved for U.S. military personnel aged 17 through 50 years. ([fda.gov](https://www.fda.gov/media/80211/download))

Other names: Adenovirus Type 4 and Type 7 Vaccine, LiveAdenovirus vaccine

Beyond the preview

Go deeper on adenovirus type 4 and type 7 vaccine, live, oral.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adenovirus type 4 and type 7 vaccine, live, oral.

Explore the full profile